Deanna Teoh1, Rachel I Vogel1, Adam Langer1, Jinai Bharucha1, Melissa A Geller1, Eileen Harwood2, Shalini Kulasingam2, Genevieve B Melton3,4. 1. Department of Obstetrics, Gynecology & Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN. 2. School of Public Health, Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN. 3. Department of Surgery, Division of Colon & Rectal Surgery, University of Minnesota, Minneapolis, MN. 4. Institute for Health Informatics, University of Minnesota, Minneapolis, MN.
Abstract
OBJECTIVE: Cervical cancer screening is often conducted in excess of current screening guidelines. The objective of this study was to evaluate the effect of an electronic health record (EHR) clinical decision support alert to decrease guideline-nonadherent cervical cancer screening beyond the age limits of screening or posthysterectomy. MATERIALS AND METHODS: The proportion of guideline-nonadherent Pap tests in women younger than 21 years or older than 65 years or posthysterectomy were compared 4 months before and 3 months after implementation of an EHR clinical decision support alert warning providers that a Pap test is not indicated. Providers could cancel the Pap test or override the alert and place the order. Provider characteristics and Pap test indications were summarized by preintervention/postintervention period using descriptive statistics. The proportions of nonindicated Pap tests were compared by intervention period and provider characteristics using generalized estimating equation models. RESULTS: In women beyond the screening age limits or posthysterectomy, a total of 388 Pap tests were ordered before intervention, and 313 tests were ordered after intervention. Proportion of guideline-nonadherent tests was similar before (62%) and after intervention (63%); thus, implementation of the clinical decision support alert did not change the proportion of guideline-nonadherent Pap tests ordered (OR = 1.08, 95% CI = 0.77-1.52). It is notable that 52% of guideline-nonadherent tests were ordered by 11 providers. Even when controlling for providers who ordered more than 1 test during the study period, multivariate analysis showed that male providers were more likely to order guideline-nonadherent Pap tests (OR = 2.30, 95% CI = 1.36-3.89); no other differences by provider characteristics were observed. CONCLUSIONS: An EHR clinical decision support alert does not decrease guideline-nonadherent cervical cancer screening. These data suggest efforts to optimize clinical decision support should be focused on other aspects of cervical cancer prevention.
OBJECTIVE: Cervical cancer screening is often conducted in excess of current screening guidelines. The objective of this study was to evaluate the effect of an electronic health record (EHR) clinical decision support alert to decrease guideline-nonadherent cervical cancer screening beyond the age limits of screening or posthysterectomy. MATERIALS AND METHODS: The proportion of guideline-nonadherent Pap tests in women younger than 21 years or older than 65 years or posthysterectomy were compared 4 months before and 3 months after implementation of an EHR clinical decision support alert warning providers that a Pap test is not indicated. Providers could cancel the Pap test or override the alert and place the order. Provider characteristics and Pap test indications were summarized by preintervention/postintervention period using descriptive statistics. The proportions of nonindicated Pap tests were compared by intervention period and provider characteristics using generalized estimating equation models. RESULTS: In women beyond the screening age limits or posthysterectomy, a total of 388 Pap tests were ordered before intervention, and 313 tests were ordered after intervention. Proportion of guideline-nonadherent tests was similar before (62%) and after intervention (63%); thus, implementation of the clinical decision support alert did not change the proportion of guideline-nonadherent Pap tests ordered (OR = 1.08, 95% CI = 0.77-1.52). It is notable that 52% of guideline-nonadherent tests were ordered by 11 providers. Even when controlling for providers who ordered more than 1 test during the study period, multivariate analysis showed that male providers were more likely to order guideline-nonadherent Pap tests (OR = 2.30, 95% CI = 1.36-3.89); no other differences by provider characteristics were observed. CONCLUSIONS: An EHR clinical decision support alert does not decrease guideline-nonadherent cervical cancer screening. These data suggest efforts to optimize clinical decision support should be focused on other aspects of cervical cancer prevention.
Authors: Natasha K Parekh; Julie M Donohue; Aiju Men; Jennifer Corbelli; Marian Jarlenski Journal: Ann Intern Med Date: 2017-07-11 Impact factor: 25.391
Authors: Deanna G K Teoh; Amity E Marriott; Rachel Isaksson Vogel; Ryan T Marriott; Charles W Lais; Levi S Downs; Shalini L Kulasingam Journal: Am J Obstet Gynecol Date: 2014-06-30 Impact factor: 8.661
Authors: Jennifer L Moss; Siddhartha Roy; Chan Shen; Joie D Cooper; Robert P Lennon; Eugene J Lengerich; Alan Adelman; William Curry; Mack T Ruffin Journal: JAMA Netw Open Date: 2020-07-01
Authors: Surbhi Shah; Sean Switzer; Nathan D Shippee; Pamela Wogensen; Kathryn Kosednar; Emma Jones; Deborah L Pestka; Sameer Badlani; Mary Butler; Brittin Wagner; Katie White; Joshua Rhein; Bradley Benson; Mark Reding; Michael Usher; Genevieve B Melton; Christopher James Tignanelli Journal: JMIR Med Inform Date: 2021-11-18